Posted on 07/30/2021 4:38:58 PM PDT by nickcarraway
A new antibody-based treatment could not only help treat COVID-19 symptoms in those already affected but potentially prevent new infections from occurring.
The treatment comes in the form of an inhaler.
A researcher at the University of Texas at Austin first developed the technology, and now an Austin-based pharmaceutical company is trying to get it on the market.
When it comes to treating infectious disease, the vaccine is the “gold standard.” However, prior to the vaccine coming on the market, scientists developed treatments for the virus, helping protect high-risk communities from COVID-19.
Current treatments require patients to get an infusion to treat COVID-19, which can take hours.
Dale Christensen, with Austin-based drug developer TFF Pharmaceuticals, says they’ve got an easy solution to getting a monoclonal antibody treatment straight to your doorstep — rather than being hooked up to a machine and IV.
“Once the capsule is punctured, you put it in, inhale into your mouth and that’s the delivery,” Christensen said. “We’re delivering it right to the lung where you need it to work.”
The technology, developed by University of Texas researcher Bill Williams, has recently demonstrated it’s successful in preventing severe illness against the delta variant.
“We are able to convert liquid forms of medication into dry powder forms,” Williams said.
In this case, the antibody called Aug-3387 is converted into dry powder and then put inside the inhaler, rapidly coating the lungs with virus-neutralizing antibodies.
Here’s what vaccinated Texans need to know about the delta variant “If somebody gets COVID, we can treat that person,” said Christensen. “We can also treat their close family members who are at high risk for developing COVID.”
TFF Pharmaceuticals is getting ready to perform toxicology studies on the device. They expect to be ready to perform human clinic trials by early 2022.
Repurposing contrails.
Amy Farrah Faller
“They expect to be ready to perform human clinic trials by early 2022”
The ‘Rona will be over long before that.
This presumes the drug is more efficacious being inhaled than by injection. That will need a fair amount of data to prove, and inhaled products can be especially difficult to get approved if it is both a novel drug and novel technology.
Trump had over 80 clinical trials of medications ongoing from Feb 2020, trying to find something that worked.
This upcoming tox study of an experimental external application of antibody is promising news. Unfortunately, it’s time to market will be about 3 years after the start of the pandemic (clinical 2022 trials mean a 2023 release/widely=avail). I sure hope CCPvirus has been ghosted before then and we won’t need an antibody inhaler.
OTOH, powdered treatments for the lungs could lead to improved and targeted treatments for lung cancer, copd and emphysema. So keep the experiments going!
EQAndyBuzz wrote:
“Amy Farrah Faller”
Who is she?
bet it will hurt the lungs, but the upside it will decrease the symptoms of a virus that 99.5% of people survive anyway.
That is frequency. Find the proper frequency that destroys a harmful cell and you have a treatment. Tesla was a genius.
It’s “Amy Farah Fowler”, a character from the TV series The Big Bang Theory. The actress who played her is a neuroscientist in real life.
Suddenly, I’m thinking masks are a good thing. Are they going to spray neighborhoods with “mosquito trucks” loaded with spike mRNa?
“Amy Farrah Faller”
Who is she?”
Neurobiologist on the Big Bang Theory.
...powdered treatments for the lungs...
______________________________________
Not sure, but isn’t budesinide administered in hospital as an inhaled powder? Thought I came across that somewhere.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.